Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer
Phase 3positiveGedatolisibAlpelisibFulvestrantPositive
AI Analysis
Summary
Celcuity announced positive Phase 3 VIKTORIA-1 trial results showing Gedatolisib combination regimens doubled the likelihood of survival without disease progression or death versus Alpelisib plus Fulvestrant in PIK3CA mutant patients with HR+/HER2- advanced breast cancer.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Gedatolisib combination regimens doubled the likelihood of survival without disease progression or death compared to Alpelisib plus Fulvestrant in PIK3CA mutant cohort
Importance:8/10
Sentiment:
0.85
Phase 3 databreast cancerpositive trial resultsPIK3CA mutation
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on June 2, 2026 8:06 PM